康柏西普治疗80岁以上高龄老年性黄斑变性患者的疗效分析  

Effect Analysis of Intravitreal Injection of Concept for Age-related Macular Degeneration in Patients Aged Above 80

作　　者：吴艺君 徐建锋[2] 刘明香[1] 范军华 WU Yijun;XU Jianfeng;LIU Mingxiang;FAN Junhua(Xiamen Humanity Hospital Fujian Medical University,Xiamen,361000,China;Department of Opthalmology,910th Hospital of PLA,Quanzhou 362000,China)

机构地区：[1]福建医科大学附属厦门弘爱医院眼科,福建厦门361000 [2]中国人民解放军联勤保障部队第九一〇医院眼科,福建泉州362000

出　　处：《中国医药指南》2023年第26期80-82,共3页Guide of China Medicine

摘　　要：目的评估80岁以上高龄老年性黄斑变性(AMD)患者玻璃体腔内注射康柏西普药物的安全性及疗效。方法收集我院眼科自2016年1月至2021年5月接受玻璃体腔内注射康柏西普药物治疗的80岁以上高龄AMD患者48例,记录玻璃体腔注药术后眼部不良反应以及全身心脑血管事件的发生率;记录其治疗前基线最佳矫正视力(BCVA)和末次随访时BCVA,记录治疗前后黄斑中心凹厚度(CMT),比较治疗前后BCVA、CMT的变化。48例高龄AMD患者在治疗前后填写中文版视功能相关生活质量量表-25,比较治疗前后视觉相关生活质量及日常视觉功能差异。结果48例高龄AMD患者中,男女分别为26、22例,共55眼接受玻璃体腔内注射康柏西普药物治疗,无视网膜脱离、眼内出血、眼内炎发生,无全身心脑血管事件如心肌梗死、脑卒中的发生。55眼玻璃体腔注射次数累积202次,平均注射次数3.67次/眼。所有患者治疗前视力≥0.05以上者比例为49.1%(27/55),治疗后为65.5%(38/55),差异有统计学意义(P=0.033)。治疗前,平均黄斑CMT为(310.44±34.76)μm,治疗后黄斑CMT为(267.04±31.99)μm,治疗前后差异有统计学意义(P<0.05)。48例患者治疗后CVRQoL-25总分(49.32±14.03)分,较治疗前的(43.45±15.49)分提高,差异有统计学意义(P<0.05)。结论80岁以上高龄AMD患者玻璃体腔内注射康柏西普药物是安全的,康柏西普治疗80岁以上高龄AMD患者可改善部分视功能、提高视功能相关的生活质量。Objective To evaluate the and safety and efficacy of intravitreal injection of concept for age-related macular degeneration in patients aged above 80.Methods Fourty-eight patients aged above 80 years old were included,and all the eyes received intravitreal injection of concept.The incidence of ocular and systemic adverse events were recorded after the treatment.Best-corrected visual acuity(BCVA),central macular thickness(CMT),and Chinese version vision-related quality of life were also measured before and after treatment.Results Among the 48 elderly patients included,the ratio of male,female was 26,22 cases.A total of 55 eyes were treated with intravitreal injection of Concept.There were no retinal detachment,intraocular hemorrhage,intraocular inflammation occured,and no adverse events such as myocardial infarction and stroke.A total of 202 intraocular injections were administered in 55 eyes,with an average of 3.67 injections per eye.The proportion of with BCVA above 0.05 was 49.1%(27/55)before treatment and 65.5%(38/55)after treatment,the difference was statistically significant(P=0.033).The mean CMT was(310.44+34.76)μm before treatment,and(267.04±31.99)μm after treatment,the difference was statistically significant(P<0.05).The average total score of CVRQoL-25 in 48 patients was(49.32±14.03)scores after treatment,compared with(43.45±15.49)scores before treatment,the difference was statistically significant(P<0.05).Conclusions For patients aged above 80yeas old,the intravitreal injection of concept is safe,it can partly improve their vision function and effectively improve the vision-related quality of life.

关 键 词：老年性黄斑变性 高龄 康柏西普 安全性 生活质量 

分 类 号：R774.5[医药卫生—眼科]